Share

|

|

|

Haplo-SCT plus dinutuximab beta ‘feasible’ for relapsed high-risk neuroblastoma

Children with relapsed, high-risk neuroblastoma may benefit from immunotherapy with dinutuximab beta after haploidentical stem-cell transplantation, investigators write in the Journal of Clinical Oncology. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
Physical frailty may be a risk factor for Parkinson’s disease, particularly in people with a high genetic risk for the condition, suggest study findings published in JAMA Neurology. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
Baricitinib has achieved largely negative results in the SLE-BRAVE trials, published in The Lancet. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
Focused ultrasound ablation of the globus pallidus internus improved symptoms in a substantial proportion of people with Parkinson’s disease in a randomised trial, but it comes with side effects. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
All articles loaded
No more articles to load

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.

showcase

MEET THE SENIOR TEAM

Lucy Piper

medwireNews Bureau Chief